POLYSTYRENELOOP
3.6.2021 19:01:08 CEST | Business Wire | Press release
A new recycling plant in the Netherlands will recycle expanded polystyrene (EPS) demolition waste and also handle a legacy additive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005924/en/
The PolyStyreneLoop recycling plant in Terneuzen, Netherlands, is scheduled to open on the 16th of June. The plant was built to prove the technical and economic feasibility of a large-scale, closed-loop solution for the recycling of EPS waste.
The PolyStyreneLoop facility will recycle EPS insulation using a physical recycling process based on the CreaSolv® Technology. This technology will turn EPS foam demolition waste from building and construction insulation (B&C) from the Netherlands, Germany and other countries into new high quality raw material. All kinds of impurities, such as cement or other construction residues, as well as the legacy additive HBCD, will be safely removed and valuable bromine recovered.
“This plant showcases how the EPS industry is always looking for ways to boost its recycling capabilities,” said Lein Tange, Co-Director of PolyStyreneLoop. “The purpose of this plant is to pave the way for the construction of similar EPS recycling plants in the rest of Europe.”
The legal structure of the plant, which benefited from a European Union LIFE programme grant, was also unique. It has been built by the PolyStyreneLoop Cooperative, a Dutch non-profit organisation whose members comprise more than 70 industry representatives from the whole polystyrene foam value chain.
The Terneuzen plant will have the capacity to recycle 3,300 metric tonnes of polystyrene foam demolition waste coming from B&C per year, validating the technical, economic, and environmental viability of a new recycling process in which polystyrene foams containing HBCD can be fully integrated in the circular economy rather than being lost from circularity.
“It’s a real plus that the plant can not only take care of current recycling waste but also legacy recycling waste,” said Jan Noordegraaf, co-director of the plant. “Moreover, we can do this with about the same energy input as mechanical recycling and the energy we use comes solely from windmills.”
The PSLoop plant will demonstrate the possibility of infinite recycling of EPS B&C waste. Later, it will also recycle extruded polystyrene, or XPS, also known as StyrofoamTM .
EPS is a lightweight foam composed of 98% air and 2% technology with outstanding protective and thermal insulation properties. In addition to building and road construction uses, it is widely used in packaging to protect everything from heavy white goods to sensitive electronics, fresh fruit and vegetables, vaccines and even bees.
About PolyStyreneLoop
PolyStyreneLoop is a cooperative representing more than 70 companies from the polystyrene foam value chain. Its members include includes polystyrene raw material producers, foam manufacturers, additives suppliers, foam converters and recyclers as well as EUMEPS, the association and voice of European Manufacturers of Expanded Polystyrene.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005924/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
